AI Engines For more Details: Perplexity Kagi Labs You
Benign Prostatic Hyperplasia (BPH): Finasteride works by inhibiting the enzyme 5-alpha reductase, which reduces the conversion of testosterone to dihydrotestosterone (DHT). By lowering DHT levels, finasteride helps reduce the size of the prostate gland, relieving symptoms of BPH such as urinary urgency, frequency, weak stream, and difficulty urinating.
Male Pattern Baldness (Androgenetic Alopecia): Finasteride is also effective in treating male pattern baldness by preventing further hair loss and promoting hair regrowth in men with mild to moderate hair loss. It works similarly to its action in BPH by reducing DHT levels, which helps to prevent hair follicle miniaturization.
Rank | Probiotic | Impact |
---|---|---|
species | Escherichia coli | Reduces |
We extend modifiers to include items that changes the parent and child taxa. I.e. for a species, that would be the genus that is belongs to and the strains in the species.
A higher number indicates impact on more bacteria associated with the condition and confidence on the impact.
We have X bacteria high and Y low reported. We find that the modifier reduces some and increases other of these two groups. We just tally: X|reduces + Y|Increase = Positive X|increases + Y|decrease = Negative.
Benefit Ratio:
Numbers above 0 have increasing positive effect.
Numbers below 0 have increasing negative effect.
Condition | Positive Impact | Negative Impact | Benefit Ratio Impact |
---|---|---|---|
ADHD | 0.7 | 0.7 | |
Age-Related Macular Degeneration and Glaucoma | 0.3 | -0.3 | |
Allergic Rhinitis (Hay Fever) | 0.4 | 0.4 | |
Allergies | 0.2 | 1.3 | -5.5 |
Allergy to milk products | 0.6 | 0.3 | 1 |
Alopecia (Hair Loss) | 0.6 | 0.6 | |
Alzheimer's disease | 0.7 | 0.7 | 0 |
Amyotrophic lateral sclerosis (ALS) Motor Neuron | 0.2 | 0.5 | -1.5 |
Ankylosing spondylitis | 1.5 | 0.5 | 2 |
Anorexia Nervosa | 0.3 | 0.5 | -0.67 |
Antiphospholipid syndrome (APS) | 0.6 | 0.6 | |
Asthma | 0.1 | -0.1 | |
Atherosclerosis | 0.4 | 0.4 | |
Atrial fibrillation | 1.2 | 0.8 | 0.5 |
Autism | 1.7 | 1.8 | -0.06 |
Barrett esophagus cancer | 0.4 | -0.4 | |
benign prostatic hyperplasia | 0 | 0 | |
Bipolar Disorder | 0.8 | 0.4 | 1 |
Brain Trauma | 0.1 | -0.1 | |
Carcinoma | 1.2 | 0.8 | 0.5 |
Celiac Disease | 0.5 | 0.8 | -0.6 |
Cerebral Palsy | 0.4 | 0.5 | -0.25 |
Chronic Fatigue Syndrome | 1.1 | 1.5 | -0.36 |
Chronic Kidney Disease | 0.4 | 0.4 | |
Chronic Lyme | 0.1 | -0.1 | |
Chronic Obstructive Pulmonary Disease (COPD) | 1.2 | 1.2 | |
Chronic Urticaria (Hives) | 0.5 | 0.6 | -0.2 |
Coagulation / Micro clot triggering bacteria | 0.7 | 0.8 | -0.14 |
Colorectal Cancer | 1.8 | 1.8 | |
Constipation | 0.1 | 0.1 | |
Coronary artery disease | 0.4 | 0.4 | |
COVID-19 | 1.8 | 3.5 | -0.94 |
Crohn's Disease | 1 | 0.9 | 0.11 |
cystic fibrosis | 0.1 | 0.1 | 0 |
deep vein thrombosis | 0.1 | 0.8 | -7 |
Depression | 2.3 | 1.6 | 0.44 |
Dermatomyositis | 0.4 | 0.4 | |
Eczema | 0 | 1.3 | 0 |
Endometriosis | 0.8 | 0.4 | 1 |
Epilepsy | 0.7 | 0.7 | 0 |
Fibromyalgia | 0.6 | 0.6 | 0 |
Functional constipation / chronic idiopathic constipation | 1 | 1.1 | -0.1 |
gallstone disease (gsd) | 0.7 | 0.7 | |
Gastroesophageal reflux disease (Gerd) including Barrett's esophagus | 0.2 | 0.4 | -1 |
Generalized anxiety disorder | 0.1 | 0.1 | 0 |
Glioblastoma | 0.4 | -0.4 | |
Graves' disease | 0.4 | 0.4 | |
Halitosis | 0.1 | 0.4 | -3 |
Hashimoto's thyroiditis | 0.1 | 0.1 | 0 |
Hidradenitis Suppurativa | 0.4 | 0.4 | |
Histamine Issues,Mast Cell Issue, DAO Insufficiency | 0.2 | 0.2 | |
hyperglycemia | 0 | 0.4 | 0 |
hypertension (High Blood Pressure | 1.2 | 0.7 | 0.71 |
Hypoxia | 0.4 | 0.4 | |
IgA nephropathy (IgAN) | 0.6 | -0.6 | |
Inflammatory Bowel Disease | 1.5 | 2.6 | -0.73 |
Insomnia | 0.5 | 0.1 | 4 |
Intelligence | 0.4 | -0.4 | |
Intracranial aneurysms | 0.8 | 0.8 | |
Irritable Bowel Syndrome | 1.1 | 0.4 | 1.75 |
Liver Cirrhosis | 1.2 | 0.9 | 0.33 |
Long COVID | 1.3 | 1.7 | -0.31 |
Lung Cancer | 0.4 | 0.4 | 0 |
ME/CFS with IBS | 0.4 | 0.1 | 3 |
ME/CFS without IBS | 0.5 | 0.7 | -0.4 |
Metabolic Syndrome | 1.8 | 1.3 | 0.38 |
Mood Disorders | 2.7 | 1.6 | 0.69 |
multiple chemical sensitivity [MCS] | 1.2 | 1.2 | |
Multiple Sclerosis | 1.8 | 2.4 | -0.33 |
Multiple system atrophy (MSA) | 0.4 | -0.4 | |
Neuropathy (all types) | 0.4 | 0 | 0 |
neuropsychiatric disorders (PANDAS, PANS) | 0 | 0 | |
Nonalcoholic Fatty Liver Disease (nafld) Nonalcoholic | 0.9 | 0.5 | 0.8 |
Obesity | 1.6 | 1.6 | 0 |
obsessive-compulsive disorder | 1.8 | 0.6 | 2 |
Osteoarthritis | 0.5 | 0.4 | 0.25 |
Osteoporosis | 0.5 | 0.1 | 4 |
pancreatic cancer | 0.4 | 0.4 | |
Parkinson's Disease | 0.7 | 1 | -0.43 |
Polycystic ovary syndrome | 0.8 | 0.8 | 0 |
Premenstrual dysphoric disorder | 0.3 | -0.3 | |
Psoriasis | 1 | 1.4 | -0.4 |
rheumatoid arthritis (RA),Spondyloarthritis (SpA) | 1.6 | 0.3 | 4.33 |
Rosacea | 0.4 | 0.4 | |
Schizophrenia | 0.8 | 0.4 | 1 |
scoliosis | 0.4 | -0.4 | |
Sjögren syndrome | 1.1 | 0.4 | 1.75 |
Sleep Apnea | 0.4 | 0.1 | 3 |
Small Intestinal Bacterial Overgrowth (SIBO) | 0.4 | 0.4 | |
Stress / posttraumatic stress disorder | 0.4 | 0.1 | 3 |
Systemic Lupus Erythematosus | 0.9 | 0.4 | 1.25 |
Tic Disorder | 0.4 | 0.4 | 0 |
Tourette syndrome | 0.1 | -0.1 | |
Type 1 Diabetes | 0.7 | 0.4 | 0.75 |
Type 2 Diabetes | 1.8 | 1.5 | 0.2 |
Ulcerative colitis | 0.6 | 0.8 | -0.33 |
Unhealthy Ageing | 0.7 | 0.7 |
This is an Academic site. It generates theoretical models of what may benefit a specific microbiome results.
Explanations/Info/Descriptions are influenced by Large Language Models and may not be accurate and include some hallucinations. Please report any to us for correction.
Copyright 2016-2024 Lassesen Consulting, LLC [2007], DBA, Microbiome Prescription. All rights served.
Permission to data scrap or reverse engineer is explicitly denied to all users. U.S. Code Title 18 PART I CHAPTER 47 Β§β―1030, CETS No.185, CFAA
Use of data on this site is prohibited except under written license. There is no charge for individual personal use. Use for any commercial applications or research requires a written license.
Caveat emptor: Analysis and suggestions are based on modelling (and thus infererence) based on studies. The data sources are usually given for those that wish to consider alternative inferences. theories and models.
Inventions/Methodologies on this site are Patent Pending.
Microbiome Prescription do not make any representations that data or analyses available on this site is suitable for human diagnostic purposes, for informing treatment decisions, or for any other purposes and accept no responsibility or liability whatsoever for such use.
This site is not Health Insurance Portability and Accountability Act of 1996 (HIPAA) compliant.